Risk factor
Very high price volatility
Profitability factor
Very weak growth
About
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks.
Target Price
The average target price of CTSO is 5.4 and suggests 571% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell